Alain Patrick Algazi

Alain Patrick Algazi

Auto-generated profile, based on publicly available information

Alain Patrick Algazi

Department of Medicine University of California San Francisco California USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2016 in Cancer
Verified
Journal Article
Open access
PDF file
AAAlain P. Algazi
Alain P. Algazi
KTKaty K. Tsai
Katy K. Tsai
ASAlexander N. Shoushtari
Alexander N. Shoushtari
RMRodrigo R. Munhoz
Rodrigo R. Munhoz
ZEZeynep Eroglu
Zeynep Eroglu
RSRyan J. Sullivan
Ryan J. Sullivan
BACKGROUND: Antibodies inhibiting the programmed death receptor 1 (PD‐1) have demonstrated significant activity in the treatment of advanced cutaneous melanoma. The efficacy and safety of PD‐1 blockade in patients with uveal melanoma has not been well characterized.METHODS: Fifty‐eight patients with stage IV uveal melanoma received PD‐1 or PD‐1 ligand (PD‐L1) antibodies between 2009 and 2015 at 9 academic centers. Patients who were evaluable for response were eligible for the analysis. Imaging was performed every 12 weeks and at the investigators' discretion. Safety and clinical efficacy outcomes, including the best overall response, progression‐free survival (PFS), and overall survival (OS), were retrospectively determined.RESULTS: Of 56 eligible patients, 48 (86%) had received prior therapy, and 35 (63%) had received treatment with ipilimumab. Three patients had an objective response to ipilimumab, and 8 had stable disease as their best response. Thirty‐eight patients (68%) received pembrolizumab, 16 (29%) received nivolumab, and 2 (4%) received atezolizumab. Objective tumor responses were observed in 2 patients for an overall response rate of 3.6% (95% confidence interval [CI], 1.8%‐22.5%). Stable disease (≥6 months) was observed in 5 patients (9%). The median PFS was 2.6 months (95% CI, 2.4‐2.8 months), and the median OS was 7.6 months (95% CI, 0.7‐14.6 months). There was no association between prior treatment with ipilimumab or liver‐directed therapy and PFS or OS. Treatment was well tolerated, and only 1 patient discontinued treatment because of toxicity.CONCLUSIONS: PD‐1 and PD‐L1 antibodies rarely confer durable remissions in patients with metastatic uveal melanoma. Clinical trial enrollment should be prioritized in this population. Cancer 2016;122:3344–3353. © 2016 American Cancer Society.

5 October 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
AAAlain P. Algazi
Alain P. Algazi
MOMegan Othus
Megan Othus
ADAdil I. Daud
Adil I. Daud
RLRoger S. Lo
Roger S. Lo
JMJanice M. Mehnert
Janice M. Mehnert
ARAntoni Ribas
Antoni Ribas

7 December 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
ARAntoni Ribas
Antoni Ribas
AAAlain Algazi
Alain Algazi
PAPaolo A. Ascierto
Paolo A. Ascierto
MBMarcus Butler
Marcus Butler
SCSunandana Chandra
Sunandana Chandra
CRCaroline Robert
Caroline Robert
Combining PD-L1 blockade with inhibition of oncogenic mitogen-activated protein kinase (MAPK) signaling may result in long-lasting responses in patients with advanced melanoma. This phase 1, open-label, dose-escalation and -expansion study (NCT02027961) investigated safety, tolerability and preliminary efficacy of durvalumab (anti–PD-L1) combined with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) for patients with BRAF-mutated melanoma (cohort A, n = 26), or durvalumab and trametinib given concomitantly (cohort B, n = 20) or sequentially (cohort C, n = 22) for patients with BRAF-wild type melanoma. Adverse events and treatment discontinuation rates were more common than previously reported for these agents given as monotherapy. Objective responses were observed in 69.2% (cohort A), 20.0% (cohort B) and 31.8% (cohort C) of patients, with evidence of improved tumor immune infiltration and durable responses in a subset of patients with available biopsy samples. In conclusion, combined MAPK inhibition and anti–PD-L1 therapy may provide treatment options for patients with advanced melanoma.

16 September 2017 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
AAAlain P. Algazi
Alain P. Algazi
RERosaura Esteve‐Puig
Rosaura Esteve‐Puig
ANAdi Nosrati
Adi Nosrati
BHBrian Hinds
Brian Hinds
AHAdele Hobbs‐Muthukumar
Adele Hobbs‐Muthukumar
ADAdil Daud
Adil Daud

1 December 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CACharu Aggarwal
Charu Aggarwal
Nabil SabaNabil Saba
Nabil Saba
AAAlain Algazi
Alain Algazi
Ammar SukariAmmar Sukari
Ammar Sukari
TSTanguy Y. Seiwert
Tanguy Y. Seiwert
RKRakesh Kumar
Rakesh Kumar
Purpose: Tumoral programmed cell death ligand-1 (PD-L1) expression is common in human papillomavirus (HPV)–associated head and neck squamous cell carcinoma (HNSCC). We assessed whether a DNA vaccine targeting HPV-16/18 E6/E7 with IL12 adjuvant (MEDI0457) combined with the PD-L1 inhibitor durvalumab could enhance HPV-specific T-cell response and improve outcomes in recurrent/metastatic HPV-16/18–associated HNSCC. Patients and Methods: In this phase Ib/IIa study, immunotherapy-naïve patients with ≥1 previous platinum-containing regimen (neoadjuvant/adjuvant therapy or for recurrent/metastatic disease) received MEDI0457 7 mg intramuscularly with electroporation on weeks 1, 3, 7, and 12, then every 8 weeks, plus durvalumab 1,500 mg intravenously on weeks 4, 8, and 12, then every 4 weeks, until confirmed progression and/or unacceptable toxicity. Coprimary objectives were safety and objective response rate (ORR; H0: ORR ≤ 15%); secondary objectives included 16-week disease control rate (DCR-16), overall survival (OS), and progression-free survival (PFS). Results: Of 35 treated patients, 29 were response evaluable (confirmed HPV-associated disease; received both agents). ORR was 27.6% [95% confidence interval (CI), 12.7–47.2; four complete responses, four partial responses]; responses were independent of PD-L1 tumor-cell expression (≥25% vs. 2-fold increase in tumor-infiltrating CD8+ T cells. Conclusions: MEDI0457 plus durvalumab was well tolerated. While the primary efficacy endpoint was not reached, clinical benefit was encouraging.

24 October 2017 in Immunotherapy
Verified
Journal Article
Closed access
DCDavid A Canton
David A Canton
SSShawna Shirley
Shawna Shirley
JWJocelyn Wright
Jocelyn Wright
RCRichard Connolly
Richard Connolly
CBChristoph Burkart
Christoph Burkart
AAAlain Algazi
Alain Algazi
Tumors evade detection and/or clearance by the immune system via multiple mechanisms. IL-12 is a potent immunomodulatory cytokine that plays a central role in immune priming. However, systemic delivery of IL-12 can result in life-threatening toxicity and therefore has shown limited efficacy at doses that can be safely administered. We developed an electroporation technique to produce highly localized IL-12 expression within tumors leading to regression of both treated and untreated lesions in animal models and in patients with a favorable safety profile. Furthermore, intratumoral tavokinogene telseplasmid electroporation can drive cellular immune responses, converting ‘cold’ tumors into ‘hot’ tumors. Clinical trials are ongoing to determine whether intratumoral tavokinogene telseplasmid electroporation synergizes with checkpoint blockade therapy in immunologically cold tumors predicted not to respond to PD-1 antibody monotherapy.